Biomedical engineers have developed an AI-based platform that designs short proteins, termed peptides, capable of binding and destroying previously undruggable disease-causing proteins. Inspired by ...

For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...

Biomedical engineers at Duke University have developed an AI-based platform that designs short proteins, termed peptides, capable of binding and destroying previously undruggable disease-causing ...

Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...

Gut bacteria-produced exopolysaccharides (EPS) help regulate metabolism by modulating gut microbiota, promoting SCFA ...

Employers need to “walk the talk” to create a healthy workplace culture that prevents and reduces obesity and lowers health ...

Galderma, the pure-play dermatology category leader, is pioneering new research into the impact of medication-driven <a target=_ ...

The tiny protein known as transthyretin can cause big problems in the body when it misfolds after secretion. While healthy transthyretin moves hormones through blood and spinal fluid, misfolded ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Glucagon-like peptide-1 receptor agonist use corresponded with risk reductions for dozens of diseases and adverse health outcomes, such as dementia and stroke, a new analysis published in Nature ...

This cohort study found that key sociodemographic, health care, and clinical factors are associated with receipt of semaglutide, a ...